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Abstract 
 
Introduction: Post-transplantation anemia (PTA) 
occurs frequently, with prevalence rates between 20 
and 60% depending on the criteria used for defining 
anemia. 
Aim of the work: We aimed to assess the prevalence 
of anemia after 6 months of transplantation in 
pediatric renal transplant patients under different 
protocols of immunosuppression, and to determine 
the impact of anemia upon long-term patient and 
graft survival. 
Patients and methods: Based on the data of 108 
renal transplants performed in our center, patients 
were categorized after 6 months according to their 
hemoglobin (Hb) levels into two groups. The first 
group with Hb more than 11gm/dl (group I, 29 
cases) and the second group with Hb less 
than11gm/dl (group II, 79cases). We compared the 
two groups regarding post transplant complications 
(rejection episodes, hypertension, diabetes mellitus, 
infections, hepatic dysfunction, and patient and 
graft survival. 
Results: we found no significant difference between 
the two groups regarding rejection episodes. 
However, the percentage of cases with chronic 
allograft nephropathy was significantly higher in the 
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anemic group. The survivors with functioning grafts 
were significantly higher in cases with normal Hb.  
Moreover, living cases with graft failure were 
significantly higher in anemic group .Graft survival 
rate was better in the non anemic group. However, 
no difference in patient survival was detected. Also, 
we found no difference between the two groups 
regarding post-transplant complications. 
Conclusions: From this study, we can conclude that 
the prevalence of post-transplant anemia is high 
pediatric renal transplant patients especially those 
receiving CNI and MMF, and it was associated with 
poorer graft outcome but no effect on patient 
survival . 
 
Key words: Renal post-transplant anemia, long 
term outcome 
 
Introduction 
 
Anemia has been implicated as an important risk 
factor for cardiovascular mortality in patients with 
CKD [1]. Post-transplantation anemia (PTA) occurs 
frequently, with prevalence rates between 20 and 
60% depending on the criteria used for defining 
anemia [2,3]. 
PTA has been associated with an increased risk for 
congestive heart failure and left ventricular 
hypertrophy in kidney transplant recipients [4,5]. 
Given the high frequency of PTA and that 
cardiovascular disease is the leading cause of death 
 with a functioning renal allograft, persistent anemia 
may be an important contributor to mortality in this 
population [6]. 
The pathogenesis of posttransplant anemia (PTA) is 
multifactorial, but declining renal function and 
failing erythropoietin synthesis are suggested to 
play an important role [7]. Late post transplantation 
anemia (PTA) has been attributed to renal 
dysfunction, immunosuppressive drugs, antiviral 
agents, infections, blood loss, autoimmune 
hemolytic anemia, chronic inflammatory state and 
the use of angiotensin-converting enzyme inhibitors 
[8-10]. 
The three recent surveys enrolling the largest 
number of patients reported a prevalence of 30-
40%. Severe anemia, requiring treatment based on 
current guidelines, is less frequent with prevalence 
rate of 10-15% [11-12]. 
Conflicting views had been published regarding the 
association between anemia and outcome in kidney-
transplanted patients. No significant association was 
found between anemia and outcome (mortality or 
graft failure [13]. However, Heinze et al [14] 
suggested that anemia may be associated with 
mortality in the kidney-transplanted patients. The 
occurrence of PTA at 1 year is harmful to patient 
survival [15]. Moreover, anemia which is a treatable 
complication is significantly and independently 
associated with mortality and graft failure in 
kidney-transplanted patients [16]. 
Anemia may also contribute to more rapid loss of 
renal function in patients with impaired renal 
function [17]. A recent study suggested that anemia 
significantly predicted the decline of renal function 
among CKD patients [18], and also among heart-
transplant recipients [19]. Furthermore, Gouva et al 
[20] have recently shown that treating anemia in 
CKD patients can slow down the decline of renal 
function. 
 
 
Aim of the work 
 
We aimed to assess the prevalence of anemia after 6 
months of transplantation in pediatric patients under 
different protocols of immunosuppression, and to 
determine the impact of anemia upon long-term 
patient and graft survival. 
 
Material and methods 
 
We included 108 pediatric renal transplant 
recipients (age < 17 years) who received live donor 
kidney transplantation in our center in the period 
between 1983 and 2005. Most, if not all patients, 
who have undergone kidney transplantation in our 
center were anemic and spontaneous correction of 
anemia was noted and nearly completed within 4-6 
months. They were categorized according to their 
hemoglobin (Hb) levels into two groups. The first 
group with Hb > 11gm/dl (group I, 29 cases) and 
the second group with Hb < 11gm/dl (group II, 79 
cases). Both groups were matched regarding 
previous blood transfusion.  
Methods: Clinical data were reviewed. 
Demographic data included recipient age and 
gender; donor age and gender; causes of end-stage 
renal disease; and HLA-A, B, & DR mismatching. 
All recipients were regularly followed up (with 
mean follow period 120±12 months). The follow up 
visits were frequent early post-transplantation and 
then gradually spaced. Each visit, the graft function 
was assessed by serum creatinine, creatinine 
clearance and urine analysis; in addition to other 
laboratory investigations including complete blood 
picture, immunosuppressive drug levels.  All 
recipients were closely and regularly followed up 
for evaluation of medical or surgical complications. 
Abdominal and Doppler ultrasound were also 
performed.  
Immunosuppression: Prednisolone was started on 
the day (-1) of transplantation at a dose of 8.5 mg / 
kg and reduced gradually till the smallest dose of 
0.15 mg / kg/day by the end of the 9
th
 month. 
Azathioprine (Aza) was given in a dose of 3 
mg/kg/day for old regimen (steroid and aza) and in 
a dose of 1.5 mg /kg /day in group of steroid, Aza, 
and Cyclosporine (CsA). Only CsA was given 2-3 
days pretransplantation. CsA was introduced in a 
dose of 8.5 mg/kg and it was adjusted to keep the 
trough level 200-250 ng/ml in the first month,       
150-200 ng/ml in the second month and 100-150 
ng/ml thereafter. Antibody induction therapy was 
given to the majority of cases according to our 
policy. Antibody induction therapy –using 
basilixmab 20mg at days 0 and 4 –was added from 
the late nineties till now.  CsA trough level was 
measured at first using Radio-immune Assay Kits, 
(Sandoz, Basel, Switzerland), and then using 
monoclonal specific antibody, (Abbott laboratories, 
Abbott Park, IL). 
Tacrolimus therapy was given at a dosage of 
0.1mg/kg/day and the dose was adjusted to achieve 
target whole-blood trough concentrations of 10-
15ng/ml during the first 2 weeks then 5-10 ng/ml 
thereafter. Tacrolimus concentrations in whole 
blood were measured by the IMx analyzer (Abbott 
laboratories, Abbott Park, IL). Mycophenolate 
Mofetil (MMF) was administered in a dose of 20-
30mg/kg twice daily.  
Graft biopsy was performed if there was any 
 clinical suspicion of rejection (unexplained rise of 
serum creatinine more than 25 % of the basal level). 
Before 1994, we were defining acute rejection into 
3 grades: mild, moderate and severe according to 
the degree of cellular infiltration in the graft. After 
1994, we followed the Banff classification with its 
modifications (acute and chronic allograft 
nephropathy).  
All acute rejection episodes were biopsy proven and 
treated by 10 mg /kg/ day methyl prednisolone for 5 
days. Steroid–resistant rejection was treated by anti-
thymocyte globulin. Plasmapheresis was added as 
an adjuvant therapy in cases of accelerated or 
vascular rejections. 
Statistical analysis: Statistical analysis was carried 
out using IBM-compatible SPSS for windows 
version 11.5 (SPSS Inc., Chicago, IL). For 
comparison of continuous data, the T-test was 
utilized. Chi-square test was employed for 
comparison of simple proportions. Patient and graft 
survival were computed using Kaplan-Meier 
technique. Differences in survival were calculated 
by the log-rank test. P value of less than 0.05 was 
considered statistically significant.  
 
Results  
 
Table (1) illustrated the donors and recipients 
characteristics. Majority of recipients were males in 
their second decade of life while nearly half of the 
donors were females in their third decade of life. 
The two groups were homogenous in terms of 
donor‘s age, sex; recipient age, prior blood 
transfusion and pre-transplant hypertension. In 
addition, no preformed antibodies against donor 
antigens were detected in the pre-transplant cross-
match of any of the study patients. The techniques 
employed for re-establishment of urinary continuity 
were also essentially similar. The two groups were 
matched regarding the type of primary 
immunosuppression protocols with the majority 
being on steroid, CsA and aza.   
Rejection episodes: No significant difference was 
found between the anemic and non-anemic groups 
regarding either those who experienced single 
rejection episode (p= 0.079); repeated rejections 
(p=0.58); cases with acute cellular rejection 
(p=0.95), acute vascular rejection (p=0.86) or 
chronic rejection (p=0.19). However, on dealing 
with anemic patients alone, we observed that the 
number of cases with chronic allograft rejection was 
significantly higher among severely anemic patients 
(p=0.025, table 2).  
Outcome: At the last follow up, the survivors with 
functioning grafts were significantly higher in cases 
with normal Hb (p=0.013). However, living cases 
with graft failure were significantly higher in 
anemic group (p=0.023, table 3). Graft survival 
rates were 98.3% in normal group vs.97.4 % in 
anemic group at 1-year; 98.1% vs. 96.1% at 5-year; 
and 93.9% vs. 82.2% at 10-year respectively (figure 
1, p< 0.001). The corresponding patient survival 
rates were 100% vs. 98.7% at 1-year; 100% vs. 
98.7% at 5-year; and 100% vs.98.7% at 10-year 
respectively (figure 2, p=0.099).  
Graft function: In spite of comparable results of 
graft function in both groups at one year (p>0.05), 
the percentage of cases with serum creatinine less 
than 1.5mg/dl, was significantly higher in group I 
(p=0.016), while the percentage of cases with serum 
creatinine more than 3 mg/dl, was significantly 
higher in group II at the last follow up (p=0.01, 
table 4).  However, both groups were matched 
regarding cases with normal graft function at the 
last follow up.  
Complications:  The two groups were comparable 
regarding post-transplant complications especially 
diabetes mellitus; serious bacterial infections, 
hepatic problems and hypertension (p>0.05, table 
5). Two cases (2.6%) died mostly due to 
cardiovascular causes in anemic group while no 
mortality was reported among patients of the other 
group. Moreover, no single case of malignancy was 
reported. 
 
Table 1: Characteristics of donors and recipients among patients of the two groups  
 
  
Group (I) 
Normal Hb 
N=29 
 
 
Group (II) 
Anemic group 
N=79 
 
p value 
 
Mean age of donors (years) 
 
34.1±9.7 
 
36.5±10 
 
0.24 
Donor  sex (male/female) 10/19 34/45 0.42 
Mean age of recipients (years) 15.07±2.4 13.9±3.3 0.39 
Recipient sex (male/female)* 20/9 55/24 0.94 
Original kidney disease: 
     -Immunological causes  
     -Non- immunological causes 
6 
23 
10 
69 
0.24 
 
 Pretransplant hypertension  12 36 0.69 
Pretransplant  blood transfusion 15 39 0.89 
Pretransplant dialysis 23 75 0.67 
HLA  type I    ≥ 50 %match 
          type II   50% match   
26 
26 
72 
75 
0.87 
0.32 
Type of immunosuppression 
     -CNI-free  
     -CsA-based  
     -Tac-based  
 
 
2 
25 
2 
 
 
1 
69 
9 
 
 
0.35 
0.87 
0.43 
 
* Only significant variable with multivariate analysis 
 
Table 2.  Rejection episodes in both groups 
 
                            
Group (I) 
Normal Hb 
N=29 
 
Group (II) 
Anemic group 
N=79 
 
 
p value 
 
One rejection 
 
 
7 
 
21 
 
 
0.79 
≥ 2 rejections 
 
3 
 
4 0.58 
Type of rejections  
-Acute vascular  
-Acute cellular  
-Chronic allograft nephropathy  
 
0 
 
2                      
 
0.95 
10               24       0.86 
3                    19                    0.19 
 
Rejection episodes in anemic patients   
                            
Mild anemia 
N=25 
 
 
Moderate anemia 
N=21 
 
Severe anemia 
N=33 
 
p value 
 
One rejection 
 
 
8 
 
2 
 
21 
 
0.29 
≥ 2 rejections 
 
1 2 1 0.29 
Type of rejections  
-Acute vascular  
-Acute cellular  
-Chronic allograft nephropathy  
 
2 
 
0 
 
0 
 
0.17 
6 5 13 0.17 
3 
 
3 13 0.025 
 
Table 3. Condition at last follow up of patients who continued primary immunosuppression 
 
  
Group (I) 
Normal Hb 
N=29 
 
 
Group (II) 
Anemic group 
N=79 
 
p value 
 
Live +function graft 
 
28 (96.6%) 
 
57 (72.2%) 
 
0.013 
 
live+ dialysis 
 
1 (3.4%) 
 
20 (25.3%) 
 
0.023 
 
Died+ function graft 
 
0 
 
1 (1.3%) 
 
0.056 
 
Died+ failed graft 
 
 
0 
 
1 (1.3%) 
 
0.056 
 
 
 
 Table 4. Clinical grading of anemic vs. non anemic patients (basal and at the last follows up) 
 
 Group (I) 
Normal Hb 
N=29 
Group (II) 
Anemic group 
N=79 
p value 
At one year 
     Grade 1 cr* <1.5     mg/dl 
     Grade 2 cr  1.5---3  mg/dl 
     Grade 3 cr   > 3      mg/dl 
 
24 (82.8%) 
5   (17.2%) 
0 
 
70 (88.6%) 
8   (10.1%) 
1   (1.3%) 
 
0.63 
0.5 
0.59 
Last follow up 
     Grade 1 cr <1.5        mg/dl 
     Grade 2 cr 1.5---3    mg/dl 
     Grade 3 cr 3—5       mg/dl 
 
6 (20.75%) 
20 (69%) 
3 (10.3%) 
 
 
19   (24.1%) 
32 (40.5%) 
28 (35.3%) 
 
0.71 
0.016 
0.01 
 
*Serum creatinine 
 
Table 5. Types of serious complications encountered among the two groups 
 
 Group (I) 
Normal Hb 
N=29 
Group (II) 
Anemic group 
N=79 
p value 
 
Malignancies   
 
0 
 
0 
 
Hepatic impairment       2 (6.9%) 1 (1.3%) 0.35 
Post-transplant  Hypertension    18(62.1%) 48 (60.8%) 0.92 
Posttx diabetes mellitus                     1 (3.4%) 1 (1.3%) 0.95 
Bacterial infections 
  
1 (3.4%) 7 (8.9%) 0.59 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Graft survival in anemic and cases with normal hemoglobin.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Patient survival in anemic and cases with normal hemoglobin. 
 Discussion 
 
Anemia in pre-transplant patients usually is a result 
of erythropoietin (EPO) deficiency, resistance to 
EPO, iron deficiency (either absolute or functional), 
and/or blood loss [21-24]. 
It is reported that anemia is a common problem in 
kidney transplant recipients and it is an independent 
risk factor for post transplant left ventricular 
hypertrophy and cardiovascular diseases [25-27]. 
The incidence of cardiovascular events (myocardial 
infarction, cardiovascular death, angina, congestive 
heart failure) is 35%, less likely in the first six 
months after transplantation in diabetic transplant 
recipients with hematocrit 30% compared to those 
with lower hematocrit levels [23]. 
Out of 108 pediatric renal transplant recipients 
enrolled in this study, we found that anemic patients 
(according to WHO classification of anemia) 
represented 53.7% (31.6% were mildly anemic, 
26.5% were moderately anemic and 41.7 % were 
markedly anemic). These results were higher than 
that reported by large multi-institutional studies 
which reported lower prevalence of anemia 30–40% 
at various times after transplantation [24] and 
38.6% in another European study from 72 European 
centers of kidney transplant recipients [11]. 
Moreover, the prevalence of severe anemia was 
8.5% compared to 41.7 % in the present study. 
However, shah et al [8] reported that there is a high 
prevalence of anemia among transplant population, 
in 45% of cases. The high prevalence of PTA 
cannot be attributed to uncorrected pretransplant 
anemia of CKD [29]. 
This coincides with our suggestion that although 
most of our patients were anemic at the time of 
transplantation, yet this factor alone can not be 
implicated as a sole factor in genesis of post-
transplant anemia. Anemia among our patients 
might be explained by multiple factors: female 
gender; calcineurin inhibitors, azathioprine, 
mycophenolate mofetil, poor graft function, acute 
rejection episodes, recent infection, and the use of 
ACE inhibitors and angiotensin II receptor blockers 
[30]. Patients who were receiving CsA based 
protocols were associated with lower Hb levels 
especially if associated with MMF or azathioprine 
which could be explained by their negative effect on 
the bone marrow [31] which was matched with 
findings of Yorgin et al 2002 Who reported that 
cyclosporine use was associated with lower Hb 
levels, an observation previously described in 
children [32]. Multivariate analysis of the previous 
factors showed that only the recipient's sex plays 
independently among our patients. 
In an Egyptian survey [33], they found that 47% of 
Egyptian healthy adolescent girls and boys were 
anemic which decreased to 30 % by the year 2000. 
Poor eating habits are the main reason for the high 
rates of anemia among adolescents in Egypt. 
The high prevalence of posttransplant anemia 
cannot be attributed to uncorrected pretransplant 
anemia of CKD as the prevalence at five years after 
kidney transplantation ranges from 30–35% in 
recipients with functioning allograft [25].  
The antiproliferative agent, azathioprine, is well 
known to cause bone marrow depression, and 
despite a different mechanism of action, MMF was 
observed to cause similar levels of anemia [28]. 
MMF use had demonstrable association with 
anemia especially when combined with CsA which 
was matched with findings of others [29].  
Cyclosporine use was associated with lower Hb 
levels, an observation previously described in 
children [30]. 
At the last follow up, we observed that the survivors 
with functioning grafts were significantly higher in 
cases of group I (p=0.013). However, living cases 
with graft failure (25.3%) were significantly higher 
in group II (p=0.023). Along the whole period of 
follow up, graft survival rates were significantly 
higher in group I (p< 0.001), however, the 
corresponding patient survival rates were 
comparable in both groups (p=0.099). 
Regarding graft survival, our results were matched 
with that reported by Molnar et al [16] who showed 
that, in a single center Hungarian study of 938 
kidney transplant recipients, the long term effects of 
anemia on patient and graft survival. During a 
follow-up of approximately 4 years, 79 patients 
(8.4%) returned to dialysis and 118 patients (12.6%) 
died with 30% of deaths resulting from infection, 
23% from cardiovascular disease, and 18% from 
malignancy. In spite of heterogeneity of 
immunosuppression, they concluded that anemia 
predicted graft failure and mortality, independently 
of estimated glomerular filtration rate, age, gender, 
time on dialysis, and other co-morbidities. 
Similarly, Chhabra et al [31] showed that PTA was 
associated with worse patient and graft survival. 
Molnar et al [16] demonstrated that the presence of 
anemia was associated with poor survival and graft 
failure in kidney transplant recipients with 1.69 
times higher chance to die within 4 years; and 2.46 
times higher chance to return to dialysis during the 
same follow-up period than patients without 
anemia. Regarding patient survival, our results were 
matched with the results of Winkelmayer et al [32] 
who did not find significant association between 
mortality and serum Hb.  
 Cases with acute cellular rejection were higher in 
the anemic group but this did not rank to statistical 
significance (p=0.06). A finding which was 
matched with that reported by Chhabra et al [30] 
who showed that PTA was associated with higher 
rates of acute rejection when compared with non-
anemic recipients.  
However, the percentage of cases with chronic 
allograft nephropathy was significantly higher in the 
anemic group (p= 0.001). The commonest cause of 
allograft loss is death of patients with functioning 
allograft (mostly due to cardiovascular events). 
Moreover, cardiovascular risk factors are also very 
relevant to the second most common cause of 
allograft loss (chronic allograft nephropathy) [33,5]. 
Similar to the CKD population, cardiovascular co-
morbidities are the leading causes of death in 
kidney transplant patients [34]. Anemia lead to 
hyperkinetic circulation, thicker left ventricular wall 
and congestive heart failure in kidney transplant 
patients. These factors were independent predictors 
of mortality in transplant population [19]. 
Our study has demonstrated that cases with graft 
failure increased significantly with advancement of 
anemia. This also was matched with that reported 
by Molnar et al [31] as they showed that each 1 g/L 
decrement in the level of serum hemoglobin 
increased the odd ratio of graft failure by 1.9% 
during the 46 months follow-up period. 
In spite of comparable results of graft function in 
both groups at one year (p>0.05), by time the 
percentage of cases with normal graft function was 
significantly higher in the non anemic group 
(p=0.001), while the percentage of cases with graft 
dysfunction was significantly higher in the anemic 
group at the last follow up (p=0.001). 
Several studies suggested that treating anemia can 
slow down the decline of renal function in patients 
with chronic kidney failure [35]. It was also notable 
that chronic hypoxia and oxidative stress are 
profibrogenic stimuli for tubular cells and 
interstitial fibroblasts, eventually representing a 
common pathway to the progression to ESRD. In 
transplant recipients, the hypoxic damage might be 
potentiated by the use of immunosuppressive 
agents, particularly calcineurin inhibitors, and by 
the concomitant presence of congestive heart 
failure, which reduces renal blood flow [19]. 
 
Conclusions: From this study, we can conclude that 
the prevalence of post-transplant anemia is high in 
pediatric renal transplant patients especially those 
receiving CNI and MMF, and it was associated with 
poorer graft outcome but no effect on patient 
survival. 
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